Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 15/20 | 0.78 |
| ▸ | RARA | P10276 | 14/20 | 0.78 |
| ▸ | RARB | P10826 | 14/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763755 | 0.92 | RARG (0.81) | RARGRARARARBSLC6A9 | |
| SCHEMBL25040440 | 0.89 | RARG (0.74) | RARGRARARARBSLC29A1SLC6A9 | |
| SCHEMBL25747751 | 0.88 | RARG (0.68) | RARGRARARARBHTTL3MBTL1 | |
| SCHEMBL27337609 | 0.88 | RARG (0.85) | RARGRARARARB | |
| SCHEMBL25040455 | 0.88 | RARG (0.73) | RARGRARARARB | |
| Trifarotene SCHEMBL381493 | 0.88 | RARG (1.00) | RARGRARARARB | |
| SCHEMBL30244638 | 0.88 | RARG (0.73) | RARGRARARARB | |
| SCHEMBL25040467 | 0.87 | RARG (0.84) | RARGRARARARB | |
| SCHEMBL382411 | 0.87 | RARG (0.98) | RARGRARARARB | |
| SCHEMBL25747806 | 0.87 | RARG (0.64) | RARGRARARARBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278956-A1 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | UGT1A4, TBK1, UGT1A7 | RARG 761/4885RARA 640/4885RARB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.